Wegovy tablets enter Australia’s medicine register in four strengths
TGA records dated November 3 list 1.5 mg, 4 mg, 9 mg and 25 mg tablets. Registration does not establish a pharmacy launch date, stock or price.
Verified brief
The story in 60 seconds
Australia’s official medicine register now lists four Wegovy semaglutide tablet strengths sponsored by Novo Nordisk Pharmaceuticals. Pharmacy Daily reports approval and an expected launch before year-end; the register entries themselves do not confirm when patients can obtain the tablets.
This brief and the full story below are based on the disclosed sources. SearchTrends Daily’s interpretation appears later under “Our take.”
Full reporting
The complete story
The Australian Register of Therapeutic Goods lists four Wegovy tablet products dated November 3, 2026: 1.5 mg, 4 mg, 9 mg and 25 mg. Each is described as a semaglutide tablet in a blister pack.
Their ARTG identifiers are 522753, 522757, 522758 and 522759 respectively. The 25 mg record names Novo Nordisk Pharmaceuticals Pty Ltd as sponsor and identifies semaglutide as the ingredient. The current register search displays the four new tablet entries alongside earlier injectable Wegovy products.
Pharmacy Daily’s November 3 report says the TGA has approved the daily semaglutide pill and that Australian availability is expected before the end of the year. That timing is a reported expectation, rather than a launch date specified in the register records.
Source perspectives
What other reporting adds
These are the reports, official records, and trend observations used to build the story. The note under each link explains exactly what it contributes.
Official register results list 1.5 mg, 4 mg, 9 mg and 25 mg tablets, with identifiers 522753, 522757, 522758 and 522759. Earlier injectable formulations appear separately.
Read original source ↗Therapeutic Goods AdministrationWEGOVY semaglutide 25 mg tablet blister pack (522759)Primary product record dated November 3, 2026, naming Novo Nordisk Pharmaceuticals Pty Ltd as sponsor and semaglutide as ingredient. It does not provide a pharmacy launch day or retail price.
Read original source ↗Pharmacy DailyPD breaking news – Wegovy weight loss pills approved — November 3, 2026The publicly accessible opening reports TGA approval of the daily pill and expected Australian availability before year-end. The remainder is subscriber-only; no additional claims are attributed to it.
Read original source ↗Therapeutic Goods AdministrationWEGOVY — original registration dated September 1, 2022Historical registration context. This older page is not evidence that the new tablet records were registered in 2022.
Read original source ↗Wikimedia Commons / News Øresund – Johan WessmanNovo Nordisk headquarters building Denmark — photograph taken June 8, 2016Licensed archival photograph of the company’s headquarters in Bagsværd, Denmark. Not a photograph of the 2026 Australian registration or tablet packaging.
Read original source ↗Creative CommonsCreative Commons Attribution 3.0 licenceLicence for the credited headquarters photograph. Attribution retained; site display may crop the original image.
Read original source ↗SearchTrends Daily opinion
Our take
Analysis
What the evidence and search signal suggest
Our assessment: the verified development is the addition of four Australian tablet registrations. Availability before year-end remains Pharmacy Daily’s reported expectation. The primary entries reviewed for this article do not establish a precise retail launch day, stock level, price or PBS subsidy decision.
Analysis and commentary are SearchTrends Daily’s interpretation. They are intentionally separated from the sourced account above.
Meaning
Why this matters
The records establish a new registered formulation in Australia. They give readers firmer evidence than overseas approval news or older Australian pages that discuss only injections.
Registration and practical access answer different questions. A listing identifies the registered product; it does not, by itself, show that a particular pharmacy has stock, what the retail price will be or whether a particular person is eligible for treatment.
Background
How we got here
The TGA’s older Wegovy registration page records an initial registration on September 1, 2022. It should not be read as the date of today’s tablet entries. The current ARTG results include both injections and tablets, so the formulation and ARTG identifier matter when comparing records.
Overseas authorisations also have their own dates and scope. They are not substitutes for checking the Australian product record.
Outlook
What is likely to happen next
Watch the linked TGA records and Novo Nordisk’s Australian announcements for product information and confirmed supply details. A strength appearing on the register is not a personal dosing instruction, and this article does not recommend starting, stopping or switching a medicine.
Image credit: © News Øresund – Johan Wessman, via Wikimedia Commons, CC BY 3.0. The photograph shows Novo Nordisk’s headquarters in Bagsværd, Denmark, on June 8, 2016. It is an archival company photograph, not an Australian approval event or a photograph of the newly registered tablets. The source image is unchanged; the site may crop its display.
A conditional editorial assessment based on the evidence available at the review date, not a guaranteed outcome.
Live record
Updates to this story
No material updates yet.
Commentary
What we think
The useful follow-up is a confirmed Australian supply announcement with clear access information. Reporting those details separately from registration will help avoid presenting approval as immediate nationwide availability.